Renaissance Technologies LLC raised its position in shares of NanoViricides Inc (NYSEAMERICAN:NNVC) by 67.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 888,372 shares of the company’s stock after buying an additional 356,872 shares during the period. Renaissance Technologies LLC’s holdings in NanoViricides were worth $391,000 as of its most recent filing with the Securities & Exchange Commission.
NYSEAMERICAN:NNVC opened at $0.38 on Friday. NanoViricides Inc has a 12-month low of $0.25 and a 12-month high of $1.23.
TRADEMARK VIOLATION WARNING: This piece was first published by WKRB News and is the property of of WKRB News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/11/09/nanoviricides-inc-nnvc-shares-bought-by-renaissance-technologies-llc.html.
NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS.
Read More: What are the most popular ETFs
Want to see what other hedge funds are holding NNVC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NanoViricides Inc (NYSEAMERICAN:NNVC).
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.